Randomized trial shows 91% reduction in seizures among children with Dravet syndrome — Evidence Review

An international clinical trial found that the investigational drug zorevunersen led to significant seizure reduction—up to 91%—in children with Dravet syndrome, with most side effects reported as mild. Related studies generally support the need for targeted therapies in severe pediatric epilepsies, though direct genetic approaches like zorevunersen represent a novel advance (original source).

• Previous research highlights ongoing challenges in controlling seizures and improving neurodevelopmental outcomes in Dravet syndrome, even with newer anti-epileptic drugs and dietary therapies, supporting the potential value of gene-targeted approaches like zorevunersen 1 4 5.
• Existing antiepileptic drugs, while effective in some cases, do not address the underlying genetic cause of Dravet syndrome and often fail to fully control seizures or improve cognitive and behavioral outcomes, highlighting the importance of the new therapy’s mechanism and its reported effects 1 2 3 4.
• Recent advances in genetic diagnosis and the introduction of new drugs (e.g., stiripentol, cannabidiol, fenfluramine) have improved management, but the proportion of drug-resistant cases remains high, underscoring the significance of a therapy that directly targets the primary mutation 4 5.

Study Overview and Key Findings

Dravet syndrome is a devastating and rare genetic epilepsy that presents early in childhood, leading to frequent, severe seizures and considerable neurodevelopmental impairment. Current therapies often fail to control the condition or improve its broader impacts on cognition and behavior. The study led by University College London and Great Ormond Street Hospital is notable as one of the first large-scale efforts to test a treatment specifically designed to address the genetic root of Dravet syndrome by increasing SCN1A protein production via the investigational drug zorevunersen. This research is particularly timely given the growing recognition of the limitations of existing therapies and the urgent need for more effective, disease-modifying options.

Property	Value
Organization	UCL, Great Ormond Street Hospital, Stoke Therapeutics, Biogen
Journal Name	The New England Journal of Medicine
Authors	Professor Helen Cross
Population	Children with Dravet syndrome
Sample Size	81 children
Methods	Randomized Controlled Trial (RCT)
Outcome	Seizure frequency, cognitive function, behavior, quality of life
Results	Seizure frequency dropped by up to 91% in treated children

Literature Review: Related Studies

To place these findings in context, we searched the Consensus paper database, which contains over 200 million research papers, using the following queries:

1. new drug epilepsy children treatment
2. seizure frequency reduction pediatric epilepsy
3. rare epilepsy drug efficacy studies

Below, we summarize key themes and findings from the literature review:

Topic	Key Findings
How effective are current and emerging therapies for Dravet syndrome and severe pediatric epilepsy?	- Newer antiepileptic drugs and dietary therapies (e.g., ketogenic diet) offer partial seizure control, but high rates of drug resistance persist in Dravet syndrome and similar epilepsies 1 4 6 7 8. - Gene-targeted and precision therapies (e.g., perampanel for SCN1A mutations) show promise, but evidence is still emerging 4 5 13.
What impact do existing antiepileptic drugs have on cognition and quality of life in children?	- Some newer drugs (e.g., lamotrigine, rufinamide) are better tolerated with respect to cognition and behavior, but most treatments do not directly address neurodevelopmental complications 2 3. - Overall improvements in quality of life remain limited unless seizures are robustly controlled 2 3 4.
What are the advantages and limitations of dietary and device-based therapies in refractory pediatric epilepsy?	- The ketogenic diet and modified Atkins diet significantly reduce seizure frequency in many children with refractory epilepsy, but tolerability and side effects can limit long-term use 6 7 8. - Neurostimulation devices (e.g., responsive neurostimulation) may help in select cases, but data in pediatric populations are sparse 9.
Where do current gaps remain in the management of pediatric drug-resistant epilepsy?	- Despite new drugs and improved protocols, approximately 20% of children continue to have uncontrolled seizures, underscoring the need for novel therapies that target disease mechanisms 3 4 5 10. - Comparative efficacy studies are limited, especially for rare genetic epilepsies, and most recent advances are adjunctive rather than curative 1 3 15.

How effective are current and emerging therapies for Dravet syndrome and severe pediatric epilepsy?

Related studies consistently highlight that while new antiepileptic drugs and dietary interventions have improved seizure management, a substantial subset of patients with Dravet syndrome remain drug-resistant. The new zorevunersen study’s large effect size and safety profile are notable, as previous approaches rarely achieved seizure reductions approaching those reported in this trial. Precision therapies such as perampanel have shown efficacy in specific genetic subtypes, but gene-targeted treatments like zorevunersen may represent a pivotal advance.

• Newer antiepileptic drugs (AEDs) such as stiripentol, cannabidiol, and fenfluramine have improved outcomes but do not eliminate drug resistance in Dravet syndrome 4.
• Dietary therapies (ketogenic, modified Atkins) are effective in reducing seizure frequency but have practical limitations and do not address the underlying genetic mutation 6 7 8.
• Precision approaches like perampanel can be particularly effective in SCN1A-related epilepsies, but their effect size (e.g., >90% reduction in ~35% of patients) is generally lower than what was observed for zorevunersen 13.
• The new study’s reported seizure reduction of up to 91% in some patients exceeds the average response rates seen with most existing treatments 1 4 7 8 13.

What impact do existing antiepileptic drugs have on cognition and quality of life in children?

The literature shows that while some newer AEDs are better tolerated in terms of cognitive and behavioral effects, most do not significantly improve neurodevelopmental outcomes in severe epilepsies like Dravet syndrome. The potential for zorevunersen to improve both seizure control and aspects of cognition and behavior is therefore a significant development.

• Lamotrigine and rufinamide are among the least likely to cause cognitive or behavioral side effects, but overall improvements in quality of life are usually modest unless seizure control is robust 2 3.
• Polytherapy and the need for high doses of multiple drugs can exacerbate side effects and impact neurodevelopment 2 3 4.
• Few treatments have demonstrated clear benefits for the cognitive and behavioral impairments associated with Dravet syndrome—an area where the new gene-targeted approach shows early promise 2 4.
• The new study's finding of improved quality of life and early cognitive/behavioral benefits stands out compared to the modest or mixed results seen with existing AEDs 2 4.

What are the advantages and limitations of dietary and device-based therapies in refractory pediatric epilepsy?

Dietary therapies, particularly the ketogenic diet, are well-established for seizure reduction in refractory pediatric epilepsy, but their tolerability and long-term adherence are concerns. Device-based therapies like responsive neurostimulation offer an alternative for some children, but data are limited, especially in genetic epilepsies like Dravet syndrome.

• The ketogenic and modified Atkins diets can lead to >50% seizure reduction in about half of children with refractory epilepsy, and complete seizure cessation in a minority 6 7 8.
• Adverse event-related discontinuation is more common with dietary therapies than with standard care, with the modified Atkins diet being somewhat better tolerated than the ketogenic diet 7.
• Responsive neurostimulation has shown promising results in isolated cases of pediatric epilepsy, but its use in Dravet syndrome is not well studied 9.
• Compared to dietary and device-based interventions, zorevunersen’s targeted mechanism and mode of administration (lumbar puncture) may offer a different risk-benefit profile 6 7 8 9.

Where do current gaps remain in the management of pediatric drug-resistant epilepsy?

Despite advances, a significant proportion of children with severe epilepsies—including Dravet syndrome—continue to experience uncontrolled seizures and neurodevelopmental decline. The literature underscores the urgent need for therapies that address the underlying disease mechanism rather than solely providing symptomatic relief.

• Approximately 20% of children with epilepsy are drug-resistant despite the availability of newer AEDs 3 5.
• Most recent advances are adjunctive therapies rather than curative, and comparative studies between treatments are limited 1 3 15.
• There is a lack of high-quality, etiology-specific data, especially for rare genetic epilepsies 10 15.
• The new study addresses these gaps by directly targeting the SCN1A mutation and reporting both seizure and quality-of-life outcomes 4 5.

Future Research Questions

Although the new trial presents promising results for zorevunersen in Dravet syndrome, further research is needed to confirm these findings in larger, longer-term studies, to explore effects on neurodevelopment, and to assess applicability to other genetic epilepsies. Understanding the broader implications and potential limitations of this novel genetic therapy will be crucial for future clinical practice.

Research Question	Relevance
What are the long-term neurodevelopmental effects of zorevunersen in children with Dravet syndrome?	The study reports early improvements in cognition and quality of life, but the durability and extent of these benefits over several years remain unknown 2 4.
How does zorevunersen compare to other gene-targeted therapies, such as antisense oligonucleotides, for rare epilepsies?	Direct head-to-head comparisons are lacking, and understanding relative efficacy, safety, and cost-effectiveness is important for clinical decision-making 4 5 13.
Can zorevunersen benefit other genetic epilepsy syndromes with SCN1A or related mutations?	Zorevunersen’s mechanism is specific to SCN1A, but related mutations may also cause severe epilepsies; broader applicability could expand treatment options for other patient groups 13.
What are the long-term safety and tolerability profiles of zorevunersen in pediatric populations?	While most side effects were mild in the trial, larger and longer studies are needed to identify rare or delayed adverse events, especially with repeated dosing 3 4 10.
How does the cost-effectiveness of zorevunersen compare to existing therapies for Dravet syndrome?	As novel genetic therapies become available, understanding their economic impact alongside clinical benefits will be important for health policy and access decisions 4 5.